NASDAQ:CBPO - China Biologic Products Stock Price, Forecast & News

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

China Biologic Products Holdings Inc (NASDAQ:CBPO) released its earnings results on Wednesday, November, 13th. The biopharmaceutical company reported $1.40 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.88 by $0.52. The biopharmaceutical company earned $136.10 million during the quarter. China Biologic Products had a net margin of 31.22% and a return on equity of 9.79%. The firm's revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.96 EPS. View China Biologic Products' Earnings History.

China Biologic Products is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for China Biologic Products.

2 brokerages have issued 12-month price objectives for China Biologic Products' shares. Their forecasts range from $62.00 to $88.00. On average, they anticipate China Biologic Products' share price to reach $75.00 in the next year. This suggests that the stock has a possible downside of 35.4%. View Analyst Price Targets for China Biologic Products.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products.

News coverage about CBPO stock has trended very negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. China Biologic Products earned a news impact score of -3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for China Biologic Products.

China Biologic Products saw a decrease in short interest in January. As of January 31st, there was short interest totalling 461,000 shares, a decrease of 11.6% from the January 15th total of 521,700 shares. Based on an average daily trading volume, of 79,600 shares, the short-interest ratio is currently 5.8 days. Approximately 2.7% of the shares of the stock are short sold. View China Biologic Products' Current Options Chain.

Some companies that are related to China Biologic Products include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Biogen (BIIB), Micron Technology (MU), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO) and The Carlyle Group (CG).

China Biologic Products' stock is owned by a number of of institutional and retail investors. Top institutional investors include York Capital Management Global Advisors LLC (2.80%), Bank of America Corp DE (2.26%), FIL Ltd (1.04%), Oxford Asset Management LLP (0.54%), Man Group plc (0.40%) and Nikko Asset Management Americas Inc. (0.32%). View Institutional Ownership Trends for China Biologic Products.

CBPO stock was sold by a variety of institutional investors in the last quarter, including Greenwoods Asset Management Ltd, Marshall Wace LLP, PNC Financial Services Group Inc., Point72 Asset Management L.P., Bank of New York Mellon Corp, AlphaCrest Capital Management LLC, UBS Asset Management Americas Inc. and FIL Ltd. View Insider Buying and Selling for China Biologic Products.

CBPO stock was bought by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Man Group plc, Goldman Sachs Group Inc., York Capital Management Global Advisors LLC, Bank of America Corp DE, Myriad Asset Management Ltd., Renaissance Technologies LLC and Pictet Asset Management Ltd.. View Insider Buying and Selling for China Biologic Products.

Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBPO stock can currently be purchased for approximately $116.13.

China Biologic Products has a market capitalization of $4.57 billion and generates $466.88 million in revenue each year. The biopharmaceutical company earns $128.06 million in net income (profit) each year or $4.02 on an earnings per share basis. China Biologic Products employs 2,187 workers across the globe.View Additional Information About China Biologic Products.

The official website for China Biologic Products is http://www.chinabiologic.com/.

China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]